Acute pharmacokinetics of first line anti-tuberculosis drugs in patients with Pulmonary Tuberculosis and in patients with Pulmonary Tuberculosis co-infected with HIV

Simple item page
dc.contributor.authorMugabo, Pierre
dc.contributor.authorHassan, Mogamat Shafick
dc.contributor.authorSlaughter, R.
dc.date.accessioned2016-01-07T08:05:09Z
dc.date.available2016-01-07T08:05:09Z
dc.date.issued2011
dc.description.abstractThe aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with pulmonary tuberculosis (PTB) and in patients with PTB and HIV during the first 24 h of treatment. Designed as a case-control study, it compares the pharmacokinetics of first line antituberculous drugs, in HIV-positive (cases) and HIV-negative (control) patients both presenting with pulmonary tuberculosis. Blood samples were collected before and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 8, 12 and 24 h after administration of drugs. Drugs plasma levels were tested using HPLC assays. Results: Fourteen HIV positive (7 males and 7 females) and 17 HIV negative (9 males and 8 females) enrolled. Rifafour, a combination tablet including rifampicin, isoniazid, pyrazinamide and ethambutol was used in HIV positive patients, CD4 counts were significantly lower, renal function mildly decreased in 85% patients and moderately decreased in 7% patients. Liver function was normal in both groups. None of these patients was on other drug therapy. In the HIV positive group isoniazid T1/2 and AUC were decreased and Cl increased whereas Tmax and Cmax were unchanged. Pyrazinamide Tmax and Cmax were significantly decreased in HIV positive patients and no significant changes were noticed in the T1/2, AUC and CL. Conclusion: The study suggest that ethambutol, pyrazinamide and rifampicin pharmacokinetics was not affected by HIV infection and that isoniazid disposition is affected by HIV.en_US
dc.description.accreditationWeb of Scienceen_US
dc.identifier.citationMugabo, P., et al. (2011). Acute pharmacokinetics of first line anti-tuberculosis drugs in patients with Pulmonary Tuberculosis and in patients with Pulmonary Tuberculosis co-infected with HIV. Journal of US-China Medical Science, 8(11): 661–666en_US
dc.identifier.issn1548-6648
dc.identifier.urihttp://hdl.handle.net/10566/2049
dc.language.isoenen_US
dc.privacy.showsubmitterfalse
dc.publisherDavid Publishingen_US
dc.rightsCopyright David Publishing. UWC has been granted the right to upload this article to the Research Repository.
dc.status.ispeerreviewedtrue
dc.subjectPharmacokineticsen_US
dc.subjectRifampicinen_US
dc.subjectIsoniaziden_US
dc.subjectEthambutolen_US
dc.subjectPyrazinamideen_US
dc.subjectHuman Immunodeficiency Virus (HIV)en_US
dc.subjectHIV infectionen_US
dc.subjectPulmonary Tuberculosisen_US
dc.subjectTuberculosisen_US
dc.titleAcute pharmacokinetics of first line anti-tuberculosis drugs in patients with Pulmonary Tuberculosis and in patients with Pulmonary Tuberculosis co-infected with HIVen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mugabo_acute phamacokinetics_2011.pdf
Size:
113.26 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.55 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (School of Pharmacy)
Prof. Pierre Mugabo